

Last updated: 28/08/2024

JPPR Referencing Guide

General style

The *Journal of Pharmacy Practice and Research* uses an adapted form of the Vancouver style of referencing as outlined in the examples below.

References should be numbered consecutively in the order in which they are first mentioned in the text. Titles of journals cited are to be abbreviated according to Medline convention.

The Journal style requires a space to be inserted before the volume number and page numbers when citing journal articles.

Avoid using abstracts as references.

Avoid citing personal communication unless it provides essential data not available from a public source. Obtain written permission from the source and in the text after the comment include in brackets: the person's name, position, and date of communication.

Information from manuscripts submitted but not accepted by a journal should be cited in the text. Ensure that there are sufficient details in the text describing the work and after obtaining written permission and verification from the source, include after the comment in brackets: unpublished observations and year.

Use endash (–) to indicate ranges (i.e., dates, pages)

Quotations must be indicated using quotation marks and including page number/s in main text (i.e., "*sed hendrerit etiam vitae tortor*"^{4(p56–57)}).

For electronic sources, include date accessed.

For additional guidance, refer to the Author Guidelines available on Wiley Online Library: <https://onlinelibrary.wiley.com/page/journal/20552335/homepage/forauthors.html>.

Refer questions to Journal Lead Kristy Parker (kparker@adpha.au)

Journal articles

Single author

Hirsch IB. Sliding scale insulin – time to stop sliding. *JAMA* 2009; **301**: 213–214.

More than 6 authors

Kairuz T, Chhim S, Hasan F, Kumar K, Lal A, Patel R, et al. Extemporaneous compounding in a sample of New Zealand hospitals. *N Z Med J* 2007; **120**: 48–56.

Organisation as author

Adverse Drug Reactions Advisory Committee. Washout or taper when switching antidepressants. *Aust Adv Drug Reactions Bull* 2009; **28**: 19.

Volume with supplement

Hassan E. Hyperglycaemia management in the hospital setting. *Am J Health Syst Pharm* 2007; **64** (suppl): S9–S14.

Paginated by issue (include issue number)

Mann JF, Green D, Jamerson K, Ruilope LM, Kuranoff SJ, Littke T, Viberti G; ASCEND Study Group. Avosentan for overt diabetic nephropathy. *J Am Soc Nephrol* 2010; **21**(3): 527–535.

Paginated with article number

Almasi J, Thiesen J, Krämer I. Physicochemical stability of durvalumab (Imfinzi®) concentrate for solution in original vials after first opening. *Pharm Technol Hosp Pharm* 2023; **8**: 2023008.

Electronic format only

Freed GL, Dunham KM, Switalski KE. Clinical inactivity among pediatricians. *Pediatrics* 2009; **123**: e605–e610.

Online ahead of print

Baroody C, Sandler M, Hong C, Madanat YF, Conley S. Evaluation of a decentralized investigational drug service pharmacist in a cancer clinical trial infusion unit. *J Oncol Pharm Pract* 2023; [online ahead of print].

<https://journals.sagepub.com/doi/10.1177/10781552231207854>.

Books, reports, monographs

Single author/editor

Feinberg D. *Pharmacy law: textbook and review*. Sydney: McGraw-Hill Education; 2007.

Kayne SB, editor. *Complementary and alternative medicine*. 2nd edition. London: Pharmaceutical Press; 2008.

Two or more authors/editors

Buchanan EC, Schneider PJ. *Compounding sterile preparations*. 3rd edition. Bethesda: American Society of Health-System Pharmacists; 2009.

Lidbury B, Mahalingam S, editors. *Gene profiles in drug design*. Boca Raton: CRC Press, Taylor & Francis Group; 2009.

Chapter in an edited book

Nairn R. Immunology. In: Brooks GF, Carroll KC, Butel JS, Morse SA, editors. *Jawetz, Melnick & Adelberg's medical microbiology*. 24th edition. New York: McGraw Hill Medical; 2007.

Organisation as author and publisher

Palliative Care Expert Group. *Therapeutic guidelines: palliative care*. Version 2. Melbourne: Therapeutic Guidelines Limited; 2010.

Government/NGO report

Department of Health, Therapeutic Goods Administration. *Evidence Guidelines: guidelines on the evidence required to support indications for listed complementary medicines*. Version 2.1. Canberra: Commonwealth of Australia; 2014.

World Health Organization (WHO). *World health statistics 2024: monitoring health for the SDGs, Sustainable Development Goals*. Geneva: WHO; 2024. Available from <https://iris.who.int/bitstream/handle/10665/376869/9789240094703-eng.pdf?sequence=1>.

Other published material

Approved product information

Zoton (lansoprazole) Australian approved product information. Sydney: Wyeth Australia. Approved 14 September 2004, safety related notification 13 April 2007.

Conference paper (presentation)

Coldron J. Pills and chills: medical management in a polar environment [abstract]. *Proceedings of the 35th National Conference of The Society of Hospital Pharmacists of*

Australia; 5–8 November 2009; Perth, Western Australia.

Conference paper (published)

Coldron J. Pills and chills: medical management in a polar environment [abstract]. *Proceedings of the 35th National Conference of The Society of Hospital Pharmacists of Australia*; 5–8 Nov 2009; Perth, Western Australia. Perth: The Society of Hospital Pharmacists of Australia; 2009: 72.

Unpublished material

In press (accepted for publication)

Lillywhite HB, Donald JA. Pulmonary blood flow regulation in aquatic snake. *Science* 2023 [in press].

Websites and electronic only material

Published document within a web site

Department of Health, Therapeutic Goods Administration. *Evidence Guidelines: guidelines on the evidence required to support indications for listed complementary medicines*. Version 2.1. Canberra: Commonwealth of Australia; 2014. Available from <<https://www.tga.gov.au/sites/default/files/cm-evidence-listed-medicines-140724.pdf>>. Accessed 24 June 2024.

Web Site

New Zealand Medicines and Medical Devices Safety Authority. Medsafe. Wellington: New Zealand Government; 2023. Available from <<https://www.medsafe.govt.nz/>>. Accessed 24 June 2024.

Software

Software should be referenced in the main text and not included in the Reference List. Include the version number (if available), publisher, and their location.

For example:

Data was analysed using Excel (Version 2212, Microsoft Corporation, Redmond, Washington, USA).